Get the Stockscreener App
3.13
2.96%
0.09
After Hours:
3.10
-0.03
-0.96%
Solid Biosciences Inc stock is traded at $3.13, with a volume of 338.30K.
It is up +2.96% in the last 24 hours and down -23.66% over the past month.
Solid Biosciences Inc is a life science company. It is engaged in the manufacturing of specialty and generic drugs. The company is involved in curing Duchenne muscular dystrophy (DMD), a genetic muscle-wasting disease predominantly affecting boys, with symptoms that usually manifest between three and five years of age. The company's pipeline products are the SB-001 and solid suit. The Company's singular focus is on developing treatments through gene therapy and other means for patients with neuromuscular and cardiac diseases. The company has categorized its programs into corrective therapies, disease-modifying therapies, and assistive devices.
See More
Previous Close:
$3.04
Open:
$3.07
24h Volume:
338.30K
Relative Volume:
0.83
Market Cap:
$125.06M
Revenue:
$14.79M
Net Income/Loss:
$-102.44M
P/E Ratio:
-1.0296
EPS:
-3.04
Net Cash Flow:
$-91.73M
1W Performance:
-5.72%
1M Performance:
-23.66%
6M Performance:
-60.83%
1Y Performance:
-57.87%
1-Day Range:
$3.04
$3.2599
1-Week Range:
$2.98
$3.36
52-Week Range:
$2.9201
$15.05
Solid Biosciences Inc Stock (SLDB) Company Profile
Name
Solid Biosciences Inc
Sector
Industry
Phone
617-337-4680
Address
500 RUTHERFORD AVENUE, CHARLESTOWN, MA
Compare SLDB with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
SLDB
Solid Biosciences Inc
|
3.13 | 125.06M | 14.79M | -102.44M | -91.73M | -3.04 |
|
VRTX
Vertex Pharmaceuticals Inc
|
481.16 | 123.91B | 10.63B | -479.80M | -1.35B | -1.99 |
|
REGN
Regeneron Pharmaceuticals Inc
|
722.07 | 78.94B | 14.20B | 4.41B | 3.54B | 38.28 |
|
ARGX
Argen X Se Adr
|
657.97 | 39.98B | 1.86B | -40.29M | -1.28B | -0.85 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
278.25 | 35.89B | 2.09B | -332.26M | 16.06M | -2.62 |
|
BNTX
Biontech Se Adr
|
119.94 | 28.75B | 3.30B | -501.07M | 1.03B | -2.1146 |
Solid Biosciences Inc Stock (SLDB) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Jan-08-25 | Initiated | Truist | Buy |
| Dec-13-24 | Initiated | Wedbush | Outperform |
| Dec-10-24 | Initiated | JMP Securities | Mkt Outperform |
| Jul-15-24 | Upgrade | JP Morgan | Neutral → Overweight |
| Jun-24-24 | Upgrade | Leerink Partners | Market Perform → Outperform |
| May-31-24 | Resumed | Piper Sandler | Overweight |
| Mar-28-24 | Initiated | William Blair | Outperform |
| Mar-15-24 | Initiated | Citigroup | Buy |
| Mar-14-24 | Upgrade | Piper Sandler | Neutral → Overweight |
| Dec-08-23 | Initiated | H.C. Wainwright | Buy |
| Jul-12-21 | Initiated | Piper Sandler | Neutral |
| May-27-21 | Initiated | Jefferies | Buy |
| Mar-16-21 | Upgrade | SVB Leerink | Mkt Perform → Outperform |
| Mar-09-21 | Initiated | Barclays | Overweight |
| Jan-08-21 | Upgrade | Credit Suisse | Underperform → Neutral |
| Jul-28-20 | Downgrade | SVB Leerink | Outperform → Mkt Perform |
| May-07-20 | Downgrade | Evercore ISI | Outperform → In-line |
| Oct-11-19 | Initiated | Evercore ISI | Outperform |
| Aug-29-19 | Downgrade | Citigroup | Neutral → Sell |
| Aug-19-19 | Upgrade | SVB Leerink | Mkt Perform → Outperform |
| Aug-16-19 | Upgrade | Chardan Capital Markets | Neutral → Buy |
| May-14-19 | Downgrade | Credit Suisse | Neutral → Underperform |
| May-14-19 | Downgrade | Goldman | Neutral → Sell |
| Feb-08-19 | Upgrade | Citigroup | Sell → Neutral |
| Feb-08-19 | Downgrade | SVB Leerink | Outperform → Mkt Perform |
| Nov-06-18 | Initiated | Citigroup | Sell |
| Sep-06-18 | Initiated | Credit Suisse | Neutral |
View All
Solid Biosciences Inc Stock (SLDB) Latest News
Examining Solid Biosciences Inc (SLDB) stock is warranted - US Post News
Insider Selling: Ganot Ilan, Solid Biosciences Inc [SLDB] Director divested 144 shares - Knox Daily
Ratio Examination: Solid Biosciences Inc (SLDB)’s Price-to-Cash and Price-to-Free Cash Flow - The Dwinnex
JMP Securities maintains Solid Biosciences stock with $15 target - MSN
Solid Biosciences Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - GlobeNewswire
Exclusive: Solid Biosciences Secures Top Talent with Strategic RSU Package - StockTitan
Solid Biosciences director Ilan Ganot sells $447 in stock - MSN
Solid Biosciences stock jumps 11% post-market on FDA update - MSN
Solid Biosciences director Ilan Ganot sells $447 in stock By Investing.com - Investing.com Australia
Solid Biosciences stock hits 52-week low at $3.02 - MSN
Solid Biosciences stock hits 52-week low at $3.02 By Investing.com - Investing.com UK
Brokers Set Expectations for SLDB FY2025 Earnings - Defense World
Solid Biosciences gets FDA Fast Track for FA gene therapy By Investing.com - Investing.com Australia
Cantor Fitzgerald Comments on SLDB FY2025 Earnings - MarketBeat
SLDB Stock Up as FDA Clears IND for SGT-212 in Friedreich's Ataxia - MSN
Solid Biosciences Inc. (NASDAQ:SLDB) Receives $15.30 Average PT from Brokerages - MarketBeat
Solid Biosciences Inc. (NASDAQ:SLDB) Receives Consensus Rating of “Buy” from Analysts - Defense World
Solid Biosciences: Differentiating Factors Of SGT-212 To Set Itself Apart - Seeking Alpha
Solid Biosciences’ Friedreich Ataxia Gene Therapy SGT-212 Garners Fast Track Designation - CGTLive™
Solid Biosciences gets FDA Fast Track for FA gene therapy - Investing.com India
Solid Biosciences' Ataxia Treatment Receives FDA Fast-Track Designation - MarketWatch
Solid Biosciences Secures FDA Fast Track Status for Novel Dual-Route Friedreich's Ataxia Gene Therapy - StockTitan
Solid Biosciences Receives FDA Fast Track Designation for - GlobeNewswire
Barclays PLC Acquires 50,582 Shares of Solid Biosciences Inc. (NASDAQ:SLDB) - Defense World
Solid Biosciences Initiates Clinical Trial For Duchenne Therapy SGT-003 - RTTNews
Solid Biosciences Outlines Key Priorities for Advancing Diversified Neuromuscular and Cardiac Development Pipeline and Establishing Leadership in Precision Genetic Medicines - The Manila Times
Solid Biosciences Advances Gene Therapy Pipeline, Reports Strong $148.9M Cash Position - StockTitan
Solid Bio draws buy from Truist on valuation and catalysts - MSN
Jane Street Group LLC Has $145,000 Stock Holdings in Solid Biosciences Inc. (NASDAQ:SLDB) - Defense World
Solid Biosciences CFO Kevin Tan sells $15,849 in company stock By Investing.com - Investing.com Australia
Solid Biosciences CFO Kevin Tan sells $15,849 in company stock - Investing.com India
Kevin Tan Sells 4,073 Shares of Solid Biosciences Inc. (NASDAQ:SLDB) Stock - MarketBeat
Solid Biosciences' SWOT analysis: gene therapy firm's stock poised for growth - Investing.com
Q1 EPS Forecast for Solid Biosciences Reduced by Analyst - Defense World
HC Wainwright Reiterates “Buy” Rating for Solid Biosciences (NASDAQ:SLDB) - Defense World
Solid Biosciences stock hits 52-week low at $3.78 By Investing.com - Investing.com Australia
Solid Biosciences (NASDAQ:SLDB) Earns Buy Rating from HC Wainwright - MarketBeat
Solid Biosciences stock hits 52-week low at $3.78 - Investing.com
Solid Biosciences to Present at the 43rd Annual J.P. Morgan Healthcare Conference - The Manila Times
Solid Biosciences Outpaces Competitors In Duchenne Gene Therapy Development (CORRECTED) - Benzinga
Solid Bio stock draws buy from Truist (SLDB:NASDAQ) - Seeking Alpha
Solid Biosciences (NASDAQ:SLDB) Earns Buy Rating from Analysts at Truist Financial - MarketBeat
Pre-market Movers: SANA, SLDB, JSPR, DRIO... - RTTNews
FDA Nod Sends Solid Biosciences (SLDB) Soaring After-Hours - Stocks Telegraph
Solid Biosciences Announces FDA IND Clearance for First-In-Industry Dual Route of Administration Gene Therapy to Treat Both Neurologic and Cardiac Manifestations of Friedreich’s Ataxia - Yahoo Finance
Solid Biosciences Inc Stock (SLDB) Financials Data
Revenue
Net Income
Cash Flow
EPS
0.82%
0.53%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):